Age: 53.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Arthritis, Condition aggravated, Gait inability, Impaired work ability, Inflammation
Clinical narrative: severe increase in auto immune disease symptoms /Condition worsened; joint and tendon inflammation affecting all joints causing contractures in hands, fingers, knees, arms, ankles; joint and tendon inflammation affecting all joints causing contractures in hands, fingers, knees, arms, ankles. Unable to walk, unable to use hands, unable to work.; joint and tendon inflammation affecting all joints causing contractures in hands, fingers, knees, arms, ankles. Unable to walk, unable to use hands, unable to work.; joint and tendon inflammation affecting all joints causing contractures in hands, fingers, knees, arms, ankles. Unable to walk, unable to use hands, unable to work.; joint and tendon inflammation affecting all joints causing contractures in hands, fingers, knees, arms, ankles. Unable to walk, unable to use hands, unable to work.; joint and tendon inflammation affecting all joints causing contractures in hands, fingers, knees, arms, ankles. Unable to walk, unable to use hands, unable to work.; This is a spontaneous report from a contactable Nurse (patient).  A 53-year-old female patient received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration, administered in arm right on 21Aug2021 16:00 (at 53-year-old) (Batch/Lot Number: FC3182) as single dose for COVID-19 immunisation, admnistered at Pharmacy or Drug Store.  Medical history included ankylosing spondylitis, hypothyroidism, rheumatoid factor (RF) positive. Known allergies: morphine; percocet; aspirin; gluten sensitive. Concomitant medication(s) included celecoxib (CELEBREX) taken for an unspecified indication, start and stop date were not reported; baclofen (BACLOFEN); levothyroxine (LEVOTHYROXINE); secukinumab (COSENTYX), all taken for an unspecified indication, start and stop date were not reported. No other vaccine in four weeks. Patient received treatment: prednisone; IV toradol; IV dilaudid; Toradol. Patient has not experienced COVID prior vaccination. On 24Aug2021 20:00 the patient experienced severe increase in auto immune disease symptoms (disability) with outcome of not recovered, tendon inflammation (disability) with outcome of not recovered, joint inflammation (disability) with outcome of not recovered, tendon pain (disability) with outcome of not recovered, unable to walk (disability) with outcome of not recovered, contractures in hands, fingers, knees, arms, ankles (disability) with outcome of not recovered, unable to work (disability) with outcome of not recovered.  The course of events was as follow: severe increase in auto immune disease symptoms: joint and tendon inflammation affecting all joints causing contractures in hands, fingers, knees, arms, ankles. Unable to walk, unable to use hands, unable to work. Events resulted in: Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Disability or permanent damage. Therapeutic measures were taken as a result of events. The patient underwent lab tests and procedures which included: Sars-cov-2 test (Nasal Swab): negative on 30Aug2021.    No follow-up attempts are needed. No further information is expected.; Sender's Comments: Based on the information provided in the narrative, a causal association between the suspect drug and the events cannot be completely excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.